|
Orthologous residues
|
|
FANCD2 (human): S331‑p, FANCD2 iso2 (human): S331‑p, FANCD2 (mouse): S329‑p, FANCD2 (chicken): S334‑p
|
|
Characterization
|
|
Methods used to characterize site in vivo:
mass spectrometry, mutation of modification site, phospho-antibody, western blotting
|
|
Disease tissue studied:
Fanconi's anaemia
|
|
Relevant cell lines - cell types - tissues:
BD180 (lymphoblast), EUFA143, EUFA868, GM6914 (fibroblast), HeLa (cervical), HSC72, PD20
|
|
Cellular systems studied:
cell lines
|
|
Species studied:
human
|
|
Enzymes shown to modify site in vitro:
|
|
|
|
Upstream Regulation
|
|
Potential in vivo enzymes for site:
|
|
Type
|
Enzyme
|
Evidence
|
Notes
|
|
KINASE
|
Chk1 (human)
|
pharmacological inhibitor of upstream enzyme
|
|
|
|
Treatments, proteins and their effect on site modification:
|
|
Treatments
|
Referenced Treatments
|
Manipulated Protein
|
Referenced Protein
|
Effect
|
Notes
|
|
mitomycin C
|
|
|
|
increase
|
|
|
SB218078
|
mitomycin C
|
|
|
inhibit treatment-induced increase
|
|
|
|
Downstream Regulation
|
|
Effect of modification (function):
molecular association, regulation, ubiquitination
|
|
Modification regulates interactions with:
|
|
Interacting molecule
|
Interacting domains
|
Effect
|
Consequences (function)
|
Consequences (process)
|
Detection assays
|
|
BRCA2 (human)
|
|
Induces
|
|
|
co-immunoprecipitation
|
|
|
Comments:
confers resistance to mitomycin C
|
